Brief: Radius Announces First Patient Randomized In The RAD011 Pivotal Trial For Prader-Willi Syndrome

Radius Recycling

07/07/2022 13:02

July 7 (Reuters) - Radius Health Inc  RDUS.O :
    * RADIUS ANNOUNCES FIRST PATIENT RANDOMIZED IN THE RAD011
PIVOTAL
TRIAL FOR PRADER-WILLI SYNDROME
    * RADIUS HEALTH INC - SCOUT-015 CLINICAL TRIAL CURRENTLY HAS
9
ACTIVATED US SITES AND PATIENT SCREENING COMMENCED
    * RADIUS HEALTH INC - RAD011 HAS ORPHAN DRUG DESIGNATION AND
HAS
BEEN GRANTED FAST TRACK BY FDA
    * RADIUS HEALTH INC - WILL PROVIDE ADDITIONAL UPDATES
REGARDING
PWS TRIAL WITH FURTHER ADVANCEMENTS OF PROGRAM

Source text for Eikon:  ID:nGNX9L5SVL 
Further company coverage:  RDUS.O